Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy
Abstract Ovarian cancer stands as the deadliest gynecologic malignancy, responsible for nearly 65% of all gynecologic cancer-related deaths.The challenges in early detection and diagnosis, coupled with the widespread Crystals intraperitoneal spread of cancer cells and resistance to chemotherapy, contribute significantly to the high mortality rate o